Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie
PubMed
28319072
DOI
10.1038/bmt.2017.19
PII: bmt201719
Knihovny.cz E-zdroje
- MeSH
- analýza přežití MeSH
- dárci tkání MeSH
- lidé středního věku MeSH
- lidé MeSH
- myelodysplastické syndromy mortalita terapie MeSH
- následné studie MeSH
- příprava pacienta k transplantaci metody mortalita MeSH
- retrospektivní studie MeSH
- senioři MeSH
- sourozenci MeSH
- studie případů a kontrol MeSH
- testování histokompatibility MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
This study shows the long-term updated outcomes of a multicenter retrospective study which analyzed 843 patients with myelodysplastic syndrome (MDS) who underwent transplantation with an HLA-identical sibling donor with either reduced-intensity conditioning (RIC) in 213 patients, or standard myeloablative conditioning (MAC) in 630 patients. In multivariate analysis, the 13-year relapse rate was significantly increased after RIC (31% after MAC vs 48% in RIC; HR, 1.5; 95% CI, 1.1-1.9; P=0.04), but with no differences in overall survival (OS) (30% after MAC vs 27% in RIC; P=0.4) and PFS (29 vs 21%, respectively, P=0.3). Non-relapse mortality was higher in MAC (40 vs 31%; P=0.1), especially in patients older than 50 years (50 vs 33%, P<0.01). In addition, long-term follow-up confirms the importance of other variables on 13-year OS, mainly MDS risk category, disease phase, cytogenetics and receiving a high donor cell dose, irrespective of the conditioning regimen used.
A O U Citta della Salute e della Scienza di Torino Torino Italy
CHU de Lille CIRIC INSERM U995 Université de Lille 2 Lille France
EBMT Data Office Leiden The Netherlands
Fondazione IRCCS Policlinico San Matteo Pavia Italy
GKT School of Medicine London UK
Hadassah University Hospital Jerusalem Israel
Hôpital Haut Leveque Pessac France
Hospital Clinic Barcelona Spain
Hospital de la Princesa Madrid Spain
Hospital Santa Creu i Sant Pau Barcelona Spain
HUCH Comprehensive Cancer Center Helsinki Finland
Institute of Hematology and Blood Transfusion Prague Czech Republic
Leiden University Hospital Leiden The Netherlands
Medizinische Universitaet Wien Vienna Austria
Ospedale San Martino Genova Italy
Radboud University Nijmegen Medical Center Nijmegen The Netherlands
Universite Paris 4 Hopital la Pitié Salpêtrière Paris France
University Hospital Eppendorf Hamburg Germany
University Hospital Essen Germany
University Hospital Gasthuisberg Leuven Belgium
Zobrazit více v PubMed
Bone Marrow Transplant. 2010 Mar;45(3):450-7 PubMed
Semin Oncol. 2011 Oct;38(5):693-704 PubMed
Blood. 2014 Apr 10;123(15):2333-42 PubMed
Biol Blood Marrow Transplant. 2009 Feb;15(2):205-13 PubMed
J Clin Oncol. 2011 Jun 1;29(16):2230-9 PubMed
Blood. 2012 Jun 14;119(24):5632-9 PubMed
Blood. 2013 Oct 24;122(17):2943-64 PubMed
Biol Blood Marrow Transplant. 2014 Jan;20(1):111-7 PubMed
Bone Marrow Transplant. 2013 Jun;48(6):761-70 PubMed
Leukemia. 2010 May;24(5):1050-2 PubMed
Wien Klin Wochenschr. 2014 Jan;126(1-2):23-9 PubMed
Biol Blood Marrow Transplant. 2015 Mar;21(3):412-20 PubMed
Am J Hematol. 2010 Aug;85(8):579-83 PubMed
Leukemia. 2013 Mar;27(3):604-9 PubMed
Blood. 2012 Aug 9;120(6):1327-33 PubMed
Haematologica. 2014 Oct;99(10):1582-90 PubMed
Curr Opin Oncol. 2010 Mar;22(2):150-4 PubMed
Am J Hematol. 2013 Jul;88(7):581-8 PubMed
Haematologica. 2006 Nov;91(11):1513-22 PubMed
Leuk Res. 2014 Jan;38(1):57-64 PubMed
Bone Marrow Transplant. 2016 Jun;51(6):771-7 PubMed
Blood. 2006 Aug 1;108(3):836-46 PubMed
PLoS One. 2013 Oct 07;8(10):e74368 PubMed
